Advanced non-small cell lung cancer patients receiving Lilly's Gemzar plus cisplatin had a median time to disease progression of 5.2 months, compared with 3.7 months for cisplatin alone, according to labeling incorporating FDA's Aug. 26 approval of a first-line NSCLC indication.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
